patient view
This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.
drug
ONTRUZANT
Marketedupdated 2mo agoby Samsung Bioepis Co Ltd
Approvedcommunity read0 votes
all catalysts(5)
approval · 5
Jan 18, 2019
approval
ONTRUZANT (TRASTUZUMAB-DTTB) — FDA approval
ONTRUZANT
→
Mar 19, 2020
approval
ONTRUZANT (TRASTUZUMAB-DTTB) — FDA approval
ONTRUZANT
→
Feb 28, 2025
approval
ONTRUZANT (TRASTUZUMAB-DTTB) — FDA approval
ONTRUZANT
→
Dec 5, 2025
approval
ONTRUZANT (TRASTUZUMAB-DTTB) — FDA approval
ONTRUZANT
→
Apr 15, 2026
approval
ONTRUZANT (TRASTUZUMAB-DTTB) — FDA approval
ONTRUZANT
→
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that